Novel diarylsulfone non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus
CA 2303429 A1 · Owner: University Of The Sciences In Philadelphia · Inventors: Zanger, Murray
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In accordance with the present invention there is now provided novel anti-HIV , compounds of formulae selected from the group consisting of: (I) (II), (III), (IV) and (V) wherein R1 is hydrogen or C1-C4 alkyl; R2 is hydrogen C1-C4 , alkyl, C1-C4 alkoxy or halogen; R3 is hydrogen hydroxy, C1-C4 alkyl, C1-C4 , alkoxy or halogen; R4 is hydrogen or halogen; R5 is hydrogen; C1-C4 alkoxy nitro, halogen or haloalkyl; R6 is hydrogen or nitro; R7 is hydrogen or C1-C4 alkyl, C1-C4 alkoxy, nitro or halogen; R8 is hydrogen hydroxy, C1-C4 alkyl, C1-C4 alkoxy or halogen; R9 is hydrogen or nitro; R10 is hydrogen or halogen; R11 is hydrogen, C1-C4 amin; R12 is hydrogen C1-C4 alkyl or halogen; R13 is , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 29, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 29, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 29, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.